The agreement enables SOTIO to license multiple fully human bispecific antibodies from Biocytogen’s RenLite platform.
SOTIO Biotech Signs Research and License Agreement with Biocytogen for Development of Next-Generation Antibody-Drug Conjugates
Leave a comment
